Zevra Therapeutics, Inc. (ZVRA)
| Market Cap | 706.07M +36.7% |
| Revenue (ttm) | 136.07M +119.4% |
| Net Income | 57.25M +2,103.6% |
| EPS | 0.96 |
| Shares Out | 59.38M |
| PE Ratio | 12.38 |
| Forward PE | 14.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 924,663 |
| Open | 12.04 |
| Previous Close | 12.13 |
| Day's Range | 11.86 - 12.18 |
| 52-Week Range | 7.16 - 15.04 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 25.00 (+110.26%) |
| Earnings Date | Aug 5, 2026 |
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 110.26% from the latest price.
News
Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
MIPLYFFA's U.S. launch is driving growth in both adult and pediatric Niemann-Pick type C patients, with integrated strategies expanding the addressable market. European expansion is ongoing, and the pipeline includes a late-stage program for Vascular Ehlers-Danlos Syndrome. Strong financials support disciplined investment and targeted business development.
Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
Guggenheim analyst Eddie Hickman lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $24 and keeps a Buy rating on the shares.
Zevra Therapeutics price target raised to $28 from $25 at Citizens
Citizens raised the firm’s price target on Zevra Therapeutics (ZVRA) to $28 from $25 and keeps an Outperform rating on the shares. Zevra reported strong Q2 results driven by MIPLYFFA…
Zevra Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA U.S. sales and expanding adoption across both adult and pediatric NPC patients. Cash reserves reached $260.2 million, supporting ongoing investments and pipeline progress, while the company advances EU regulatory efforts for arimoclomol.
Zevra Therapeutics Earnings release: Q2 2026
Zevra Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zevra Therapeutics Quarterly report: Q2 2026
Zevra Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 milli...
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-w...
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutic...
Spruce Biosciences appoints Quartel as Chief Medical Officer
Spruce Biosciences (SPRB) announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Quartel joins Spruce from Zevra Therapeutics (ZVRA), where he served as Ch...
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
Guggenheim lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $29 and keeps a Buy rating on the shares after having caught up with management following the…
Zevra Therapeutics price target lowered to $24 from $27 at BTIG
BTIG analyst Kambiz Yazdi lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $27 and keeps a Buy rating on the shares. The firm is citing the…
Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $20 from $29 and keeps a Buy rating on the shares. The firm updated its model following the European…
EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
After Zevra Therapeutics (ZVRA) announced that the EMA’s Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application, or MAA, for arimoclomol f...
Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
08:22 EDT Zevra Therapeutics (ZVRA) down 30% at $8.78 after negative CHMP opinion on arimoclomol
Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
Zevra Therapeutics (ZVRA) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a negative opinion regarding the marketing…
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Pr...
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people ...
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
Zevra Therapeutics (ZVRA) announced the publication of “Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy” in Molecular Genetics and Met...
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Gene...
Zevra Therapeutics chief medical officer to step down
Zevra Therapeutics (ZVRA) announced that its chief medical officer, Adrian Quartel, will step down from his position due to personal reasons, effective July 3. Quartel will continue to support the…
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics price target raised to $35 from $25 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on Zevra Therapeutics (ZVRA) to $35 from $25 and keeps a Buy rating on the shares.